The Association of Transgelin-2, Metallothionein-2 and Ezrin With Asthma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: No intervention.
- Who it may be relevant to
- Registry conditions: Asthma. Basic parameters: 14 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
The Association of Transgelin-2, Metallothionein-2 and Ezrin With Asthma: A Case-control Study
Overview
Asthma is one of the most common chronic respiratory diseases. Previous study found a series of differentially expressed genes and proteins (transgelin-2, metallothionein-2, ezrin) in asthmatic rat. The aim of the study is to investigate the changes and associations of these gene with asthma in human.
Detailed description
This study will investigate the changes and associations in asthma. In this project, the investigators will explore the changes of gene expression of transgelin-2, metallothionein-2 and ezrin in asthma and investigate their correlation with current diagnosis markers of asthma, including pulmonary function, fractional exhaled nitric oxide,eosinophil counts,immunoglobulin E, interleukin-5, etc.
Interventions
- Diagnostic test No intervention
No intervention
Primary outcome measures
- Difference in gene expression of transgelin-2, metallothionein-2 and ezrin between controls and asthmatic patients [Time frame: Two year]
- Association of transgelin-2, metallothionein-2 and ezrin with asthma [Time frame: Two year]
Eligibility criteria
Inclusion criteria
- Males or females, aged 14-75 years;
- Patients with a definite diagnosis of bronchial asthma;
- The diagnosis of asthma according to the Global Initiative for Asthma (GINA), with positive bronchodilator responsiveness (reversibility) test;
- Healthy volunteers without respiratory symptoms such as cough, wheezing, chest tightness or dyspnea;
- Agree with all procedures in this trial by signing a written informed consent form.
Exclusion criteria
- Patients with chronic obstructive pulmonary disease or other airway disease;
- Complicated with other severe primary diseases (including hypertension, cancer, hyperthyroidism, bronchiectasia, cardiac insufficiency) and conditions that would prevent participation in the trial or put the participant at risk;
- Women who are known to be pregnant or breastfeeding;
- Not willing to participate;
- Psychiatric history and neurological disorders can not work normally;
- Other conditions that the researcher considers inappropriate to participate in this study.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-control
Study locations
China · 2 centers
- Xiangya Hospital, Central South University — Changsha
- Yueyang Hospital, Shanghai University of Traditional Chinese Medicine — Shanghai
Identifiers
NCT: NCT05496582 · SHUTCM-0806